Phosphorylated Polypeptide Inhibits Angiogenesis via Integrin Downregulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neovascular eye diseases, such as neovascular age-related macular degeneration and diabetic retinopathy, often rely on repeated intraocular injections of anti-VEGF drugs, which can lead to significant side effects and limited visual improvement in some patients, due to the complexity and chronic nature of these conditions.
Innovation Solution
Administration of a pharmaceutical composition containing a specific polypeptide with an amino acid sequence like FPGSDRF-RGD, where serine is phosphorylated, which regulates reactive oxygen species and inflammatory pathways, inhibiting angiogenesis by downregulating integrins and MMP2, offering an alternative therapeutic approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If repeated intraocular injections of anti-VEGF drugs are administered, then therapeutic effect is maintained, but treatment complexity and risk of complications increase
Solution Approach 1:
The polypeptide is designed to self-regulate through phosphorylation of serine residues, activating anti-angiogenic activity without requiring repeated external administration. The modified polypeptide autonomously exerts therapeutic effect by downregulating integrins and MMP2, reducing dependency on frequent clinical interventions
Solution Approach 2:
The polypeptide undergoes chemical modification through phosphorylation of serine residues and conjugation with RGD peptides, changing its biological properties to achieve sustained anti-angiogenic activity. This parameter change transforms the polypeptide from a transient therapeutic agent to a long-acting treatment that reduces injection frequency
2Reliability
If repeated intraocular injections are performed, then disease progression is controlled, but risk of complications increases
Solution Approach 1:
The RGD peptide conjugate acts as an intermediary that enhances the polypeptide's targeting capability to neovascular tissues. This intermediary structure facilitates specific binding to integrin receptors on endothelial cells, improving therapeutic efficacy while reducing off-target effects and complications
Solution Approach 2:
The phosphorylated serine residues enable the polypeptide to self-activate and exert sustained anti-angiogenic effects without requiring repeated external stimulation. This self-service mechanism reduces the frequency of medical interventions and associated complications
3Manufacturing precision
If conventional anti-VEGF treatment is used, then initial visual improvement is achieved, but long-term visual recovery remains poor
Solution Approach 1:
The polypeptide undergoes structural modification through phosphorylation and RGD conjugation, changing its pharmacokinetic and pharmacodynamic properties. These parameter changes enable sustained biological activity that addresses both short-term and long-term visual recovery needs
Solution Approach 2:
The therapeutic agent combines the polypeptide backbone with phosphorylated serine residues and RGD peptide conjugates, creating a composite molecular structure. This composite design integrates multiple functional elements that work synergistically to achieve both immediate and sustained visual improvement
4Reliability
If long-term repeated injections are required, then disease management is maintained, but patient burden increases
Solution Approach 1:
The modified polypeptide functions as a long-acting therapeutic agent that maintains disease control with reduced administration frequency. The self-activating phosphorylation mechanism and sustained release profile minimize the need for repeated patient visits and injections
Solution Approach 2:
The polypeptide is designed with excessive phosphorylation sites and multiple RGD conjugation points, ensuring sufficient therapeutic activity is achieved with fewer administrations. This partial action approach maintains effective drug levels over extended periods, reducing patient burden
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide effectively reduces vascular leakage and inflammation, providing a potential candidate for treating or preventing neovascular eye diseases with fewer side effects and improved visual outcomes compared to traditional treatments.
Implementation Method 1
the polypeptide can regulate reactive oxygen species (ROS)/NF-κB pathway in microglia to inhibit oxidative stress and inflammatory response
Implementation Method 2
the polypeptide can inhibit p-MEK1/2 and TRIM25, accelerate the degradation of SP1, and downregulate the transcription of integrins αVβ3 and MMP2 in endothelial cells
Data Source
AI summary
A method for treating or preventing a neovascular eye disease including: administering a patient in need thereof a pharmaceutical composition including a polypeptide, the peptide having an amino acid sequence I or II; I: FPGSDRF (SEQ ID NO: 1)-Z; II: X-FPGSDRF (SEQ ID NO: 1)-Z; S represents phosphorylated serine; X and Z independently represents an amino acid or an amino acid sequence; X is selected from F, (R)9 (SEQ ID NO: 2), (R)9-F (SEQ ID NO: 3), 6-aminohexanoic acid, 6-aminohexanoic acid-F, 6-aminohexanoic acid-(R)9 (SEQ ID NO: 2), 6-aminohexanoic acid-(R)9-F (SEQ ID NO: 3); and Z is selected from (G)n-RGD or A-(G)n-RGD (SEQ ID NO: 4), where n is an integer greater than or equal to 0, in the range of 0-10.